ValueQ1, 26TTMSelling/general/admin expenses13.52 M—Research & development57.81 M—Operating income-64.11 M—Non-Operating Income, Total2.43 M—Interest expense, net of interest capitalized182 K—Non-Operating Income, excl. Interest Expenses2.24 M—Unusual income/expense——Pretax income-61.69 M—Equity in earnings——Taxes28 K—Non-controlling/minority interest-268 K—After tax other income/expense——Net income before discontinued operations-61.45 M—Discontinued operations——Net income-61.45 M—Dilution adjustment0—Preferred dividends7.75 M—Diluted net income available to common stockholders-69.19 M—Basic earnings per share (Basic EPS)-1.07—Diluted earnings per share (Diluted EPS)-1.07—Average basic shares outstanding64.87 M—Diluted shares outstanding64.87 M—EBITDA-60.84 M—EBIT-64.11 M—Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)3.27 M—
Generate Biomedicines, Inc. - Common Stock
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases.